Radiation therapy for pathologic stage III Hodgkin's disease with and without chemotherapy

Ramez Farah, Harvey M. Golomb, Dennis E. Hallahan, Richard K. Desser, Melvin L. Griem, Richard Blough, John E. Ultmann, Ralph R. Weichselbaum

Research output: Contribution to journalArticlepeer-review

14 Scopus citations


Ninety-eight patients with pathological Stage (PS) III Hodgkin's disease treated between 1969 and 1984 were retrospectively analyzed. Treatment consisted of radiation therapy (RT) alone in 46 patients and combined radiation therapy and chemotherapy (CMT) in 52 patients. The median follow-up was 10 years (range 3-19 years). Fifteen-year survival for patients with Stage III1 is better than for Stage III2 patients (82% vs 53%; p = .014). Patients with Stage III1A have a favorable prognosis regardless of treatment modality. The probability of freedom from relapse at 15 years for patients with pathological Stage III1A treated with radiation therapy is 70%, compared to 83% for pathological Stage III1A patients treated with combined modality therapy (p = .56). In patients with pathological Stage III2A, III1B, and III2B relapses were less frequent with the use of combined modality therapy compared to radiation therapy. We conclude that pathological Stage III1A patients may be treated with radiation therapy alone; the other subsets of patients benefit from combined radiation and chemotherapy.

Original languageEnglish
Pages (from-to)761-766
Number of pages6
JournalInternational journal of radiation oncology, biology, physics
Issue number4
StatePublished - Oct 1989


  • Combined modality therapy
  • Radiation therapy
  • Stage III Hodgkin's disease


Dive into the research topics of 'Radiation therapy for pathologic stage III Hodgkin's disease with and without chemotherapy'. Together they form a unique fingerprint.

Cite this